Leukemia Research Foundation awards grants to 12 investigators
The Leukemia Research Foundation awarded $1.2 million in research grants.
The money — awarded through the Hollis Brownstein Research Grants Program for New Investigators — will fund dozen 1-year grants in the 2019-2020 funding cycle.
The Leukemia Research Foundation funds research intended to improve understanding of the causes of blood cancers and identify effective cures. The foundation has funded more than 500 research projects since 1946.
“Each year, federal funding becomes more difficult to secure, and new investigators with fresh, groundbreaking ideas can’t get the funding they need to develop their ideas and the data required for greater funding from the NIH and other sources,” Kevin Radelet, the foundation’s executive director, said in a press release. “Leukemia Research Foundation funding not only advances blood cancer science but also jumpstarts careers for these scientists.”
The grant recipients and their research topics are:
• Stephanie A. Berg, DO, of Cardinal Bernardin Cancer Center at Loyola Medicine — Germline mutations predispose to familial myeloproliferative neoplasms;
• M. Andres Blanco, PhD, of University of Pennsylvania School of Veterinary Medicine — Dual targeting of LSD1 and KAT6A to induce therapeutic differentiation in acute myeloid leukemia;
• Hamza Celik, PhD, of Washington University School of Medicine in St. Louis — Generation of a faithful patient-derived xenograft model of myelofibrosis for preclinical studies;
• Steven M. Chan, MD , PhD , of Princess Margaret Cancer Centre — Repurposing metformin to prevent blood cancers and cardiovascular diseases associated with TET2 mutation-driven clonal hematopoiesis;
Raffaella Di Micco, PhD, of Ospedale San Raffaele in Italy — Targeting of epigenetic drivers of immune evasion in AML relapses after allogeneic hematopoietic stem cell transplant;
• Daichi Inoue, MD, PhD, of Institute of Biomedical Research and Innovation in Japan — Understanding the role of ZRSR2 mutations in myeloid malignancies;
• Irum Khan, MD, of University of Illinois at Chicago — Targeting FOXM1 to improve treatment responses in AML;
• Yongsoo Kim, PhD, of VU University in the Netherlands — A computational framework to model cellular interplays in the tumor microenvironment of B-cell lymphoma;
• Rui Lu, PhD, of The University of Alabama at Birmingham — A novel stemness program with epigenetic dysregulation in AML;
• Michael Milyavsky, PhD, of Tel Aviv University in Israel — Harnessing stemness reporter to identify and target critical dependency genes;
• Christopher Ott, PhD, of Massachusetts General Hospital Cancer Center — Deciphering mechanisms of PAX5 addiction in lymphoma; and
• Capucine Van Rechem, PhD, of Stanford University School of Medicine — Identify new functions for PRMT5 in B-cell lymphoma to unravel therapeutic strategies.